Підтверджена електронна адреса в
Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response
C Miroux, T Vausselin, N Delhem
Expert opinion on biological therapy 10 (11), 1563-1572, 2010
Phenylboronic-acid-modified nanoparticles: potential antiviral therapeutics
M Khanal, T Vausselin, A Barras, O Bande, K Turcheniuk, M Benazza, ...
ACS applied materials & interfaces 5 (23), 12488-12498, 2013
High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.
BCF Edwards MR, Pietzsch C, Vausselin T, Shaw ML, Bukreyev A
ACS Infect Dis 1 (8), 380-387, 2015
The antimalarial ferroquine is an inhibitor of hepatitis C virus
T Vausselin, N Calland, S Belouzard, V Descamps, F Douam, F Helle, ...
Hepatology 58 (1), 86-97, 2013
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
T Vausselin, K Séron, M Lavie, AA Mesalam, M Lemasson, S Belouzard, ...
Journal of virology 90 (19), 8422-8434, 2016
New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore monensin A
L Fénéant, J Potel, C François, F Sané, F Douam, S Belouzard, N Calland, ...
Journal of virology 89 (16), 8346-8364, 2015
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
M Khanal, A Barras, T Vausselin, L Fénéant, R Boukherroub, ...
Nanoscale 7 (4), 1392-1402, 2015
SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses
D Dornfeld, AH Dudek, T Vausselin, SC Günther, JF Hultquist, S Giese, ...
Scientific reports 8 (1), 1-13, 2018
Claudin-6 and occludin natural variants found in a patient highly exposed but not infected with hepatitis C virus (HCV) do not confer HCV resistance in vitro
L Fénéant, J Ghosn, B Fouquet, F Helle, S Belouzard, T Vausselin, ...
PloS one 10 (11), e0142539, 2015
597 Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, 598 Wychowski C, Biot C, Dubuisson J. 2013. The antimalarial ferroquine is an inhibitor 599 of …
T Vausselin, N Calland, S Belouzard, V Descamps, F Douam, F Helle, ...
Hepatology 58, 86-97, 0
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
M Dent, K Hamorsky, T Vausselin, J Dubuisson, Y Miyata, Y Morikawa, ...
Cellular and molecular gastroenterology and hepatology 11 (1), 185-198, 2021
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
S Belouzard, A Machelart, V Sencio, T Vausselin, E Hoffmann, ...
bioRxiv, 2021
The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif
K Hervouet, M Ferrié, M Ankavay, C Camuzet, V Alexandre, A Dembélé, ...
bioRxiv, 2021
A DNA Vaccine Expressing Fusion Protein E2-NT (gp96) Induces Hepatitis C Virus Cross-Neutralizing Antibody in BALB/c Mice
E Kord, J Dubuisson, T Vausselin, AA Amirzargar, MS Yekaninejad, ...
Hepatitis Monthly 19 (9), 2019
Composés pour la prévention ou le traitement des infections par des virus de la famille des Flaviviridae
GY Vausselin T, Dubuisson J, Biot C, Wychowski C
WO Patent 2013156957 A1, 2013
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral
M Khanal, T Vausselin, A Barras, O Bande, K Turcheniuk, M Benazza, ...
This journal is© The Royal Society of Chemistry 2017
J Zhanga, Y Okamura
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–17